Company Profile
Ocularis Pharma, Inc.
Ophthalmic
Drug Development
2436 S 6th Ave
North Riverside, IL 60546
USA
www.ocularispharma.com
|
Incorporated in 2002
5 Employees
|
Privately Held
|
|
This Year's Highlights
- Completed NOVA (Night Optics and Vision Assessment) Study in 5 distinct groups of 20 subjects each (100 subjects in total) demonstrating statistically significant improvement in high and low contrast visual acuity in dim light by reducing pupil size.
- Completed dose ranging Phase 2 clinical study of Nyxol(tm) Eye Drops in patients with night vision complaints.
- Completed two Phase 2 clinical studies of VisiGel(tm) Contact Lens Conditioner demonstrating statistically significant improvement in distance and near vision compared to placebo, and comfort compared to placebo.
|
Anticipated Highlights
- 24 patient Phase 2 clinical study in patients with severe night vision complaints is underway. Visual performance in dim light will be measured 4 ways: contrast sensitivity, low contrast visual acuity, wavefront aberrometry, and subjective questionnaire.
|
|
Corporate Mission
To develop and commercialize products that improve vision quality and performance.
|
